tetano
Editor, Senior Moderator
Infection
. 2022 Sep 9.
doi: 10.1007/s15010-022-01914-8. Online ahead of print.
Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study
Nikolaus Kneidinger[SUP] 1 [/SUP], Matthias Hecker[SUP] 2 [/SUP], Vasiliki Bessa[SUP] 3 [/SUP], Ina Hettich[SUP] 4 [/SUP], Alexandra Wald[SUP] 5 [/SUP], Sabine Wege[SUP] 6 [/SUP], Anna-Barbara Nolde[SUP] 7 [/SUP], Maike Oldigs[SUP] 8 [/SUP], Zulfiya Syunyaeva[SUP] 9 [/SUP], Heinrike Wilkens[SUP] 10 [/SUP], Jens Gottlieb[SUP] 11 [/SUP]
Affiliations
Abstract
Purpose: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is currently the major threat for immunocompromised individuals. The course of COVID-19 in lung transplant recipients in the Omicron era remains unknown. The aim of the study was to assess outcome and associated factors in lung transplant recipients in a German-wide multicenter approach.
Methods: All affected individuals from January 1st to March 20th, 2022 from 8 German centers during the Omicron wave were collected. Baseline characteristics and antiviral measures were associated with outcome.
Results: Of 218 patients with PCR-proven SARS-CoV-2 infection 166 patients (76%) received any early (< 7 days) antiviral therapy median 2 (interquartile range 1-4) days after symptom onset. Most patients received sotrovimab (57%), followed by remdesivir (21%) and molnupiravir (21%). An early combination therapy was applied in 45 patients (21%). Thirty-four patients (16%) developed a severe or critical disease severity according to the WHO scale. In total, 14 patients (6.4%) died subsequently associated with COVID-19. Neither vaccination and antibody status, nor applied treatments were associated with outcome. Only age and glomerular filtration rate < 30 ml/min/1.73m[SUP]2[/SUP] were independent risk factors for a severe or critical COVID-19.
Conclusion: COVID-19 due to Omicron remains an important threat for lung transplant recipients. In particular, elderly patients and patients with impaired kidney function are at risk for worse outcome. Prophylaxis and therapy in highly immunocompromised individuals need further improvement.
Keywords: COVID-19; Immunosuppression; Lung; Omicron; Transplantation.
. 2022 Sep 9.
doi: 10.1007/s15010-022-01914-8. Online ahead of print.
Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study
Nikolaus Kneidinger[SUP] 1 [/SUP], Matthias Hecker[SUP] 2 [/SUP], Vasiliki Bessa[SUP] 3 [/SUP], Ina Hettich[SUP] 4 [/SUP], Alexandra Wald[SUP] 5 [/SUP], Sabine Wege[SUP] 6 [/SUP], Anna-Barbara Nolde[SUP] 7 [/SUP], Maike Oldigs[SUP] 8 [/SUP], Zulfiya Syunyaeva[SUP] 9 [/SUP], Heinrike Wilkens[SUP] 10 [/SUP], Jens Gottlieb[SUP] 11 [/SUP]
Affiliations
- PMID: 36083405
- DOI: 10.1007/s15010-022-01914-8
Abstract
Purpose: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is currently the major threat for immunocompromised individuals. The course of COVID-19 in lung transplant recipients in the Omicron era remains unknown. The aim of the study was to assess outcome and associated factors in lung transplant recipients in a German-wide multicenter approach.
Methods: All affected individuals from January 1st to March 20th, 2022 from 8 German centers during the Omicron wave were collected. Baseline characteristics and antiviral measures were associated with outcome.
Results: Of 218 patients with PCR-proven SARS-CoV-2 infection 166 patients (76%) received any early (< 7 days) antiviral therapy median 2 (interquartile range 1-4) days after symptom onset. Most patients received sotrovimab (57%), followed by remdesivir (21%) and molnupiravir (21%). An early combination therapy was applied in 45 patients (21%). Thirty-four patients (16%) developed a severe or critical disease severity according to the WHO scale. In total, 14 patients (6.4%) died subsequently associated with COVID-19. Neither vaccination and antibody status, nor applied treatments were associated with outcome. Only age and glomerular filtration rate < 30 ml/min/1.73m[SUP]2[/SUP] were independent risk factors for a severe or critical COVID-19.
Conclusion: COVID-19 due to Omicron remains an important threat for lung transplant recipients. In particular, elderly patients and patients with impaired kidney function are at risk for worse outcome. Prophylaxis and therapy in highly immunocompromised individuals need further improvement.
Keywords: COVID-19; Immunosuppression; Lung; Omicron; Transplantation.